PE20211890A1 - Arn bicatenario y usos del mismo - Google Patents
Arn bicatenario y usos del mismoInfo
- Publication number
- PE20211890A1 PE20211890A1 PE2021001105A PE2021001105A PE20211890A1 PE 20211890 A1 PE20211890 A1 PE 20211890A1 PE 2021001105 A PE2021001105 A PE 2021001105A PE 2021001105 A PE2021001105 A PE 2021001105A PE 20211890 A1 PE20211890 A1 PE 20211890A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- ribonucleotide
- rna
- antisense
- ataxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a una molecula de acido ribonucleico (ARN) que comprende una secuencia de ribonucleotidos antisentido con las bases apareadas a una secuencia de ribonucleotidos sentido, en donde el ribonucleotido de la secuencia de ARN antisentido es complementario a un ribonucleotido correspondiente de un ARNm de ataxina-3 humana mutante que comprende un polimorfismo de un solo nucleotido en el desequilibrio de ligamiento con un alelo de la enfermedad de Machado-Joseph (MJD) del gen de ataxina-3 humana mutante, en el que el ribonucleotido de la secuencia de ARN antisentido esta a 10 ribonucleotidos de distancia del ribonucleotido en el extremo 5' de la secuencia de ARN antisentido. La secuencia de ribonucleotidos antisentido de la molecula de ARN tiene la secuencia de nucleotidos SEQ ID NO: 2, 3, 4, 5, 6, 14, 15, 16, 17 o 18 y es complementaria a la secuencia de nucleotidos SEQ ID NO: 1 o 13. Tambien se refiere a un vector que lo contiene, en particular, el vector viral adenoasociado serotipo 9 (AAV9) como vector de administracion de genes, tras lo cual los ARN bicatenarios de la invencion pueden administrarse al sistema nervioso central (SNC) mediante vias minimamente invasivas (por ejemplo, administracion intravenosa), dado que este serotipo particular atraviesa eficazmente la barrera hematoencefalica (BHE). La presente invencion usa tecnologia de silenciamiento de ARN (por ejemplo, interferencia de ARN) contra polimorfismos de un solo nucleotido (SNP) exonicos en el gen de ataxina-3, que codifica para la proteina ataxina-3 mutante de ganancia funcional dominante, dando como resultado de ese modo un tratamiento eficaz contra la MJD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT11525319 | 2019-01-09 | ||
PCT/IB2020/050141 WO2020144611A1 (en) | 2019-01-09 | 2020-01-09 | Double stranded rna and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211890A1 true PE20211890A1 (es) | 2021-09-22 |
Family
ID=69650650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001105A PE20211890A1 (es) | 2019-01-09 | 2020-01-09 | Arn bicatenario y usos del mismo |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220098592A1 (es) |
EP (1) | EP3908658A1 (es) |
JP (1) | JP2022516779A (es) |
CN (1) | CN113302302A (es) |
AU (1) | AU2020206617A1 (es) |
BR (1) | BR112021013109A2 (es) |
CA (1) | CA3125310A1 (es) |
CL (1) | CL2021001680A1 (es) |
CO (1) | CO2021007901A2 (es) |
IL (1) | IL284717A (es) |
MX (1) | MX2021008331A (es) |
PE (1) | PE20211890A1 (es) |
WO (1) | WO2020144611A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114958850B (zh) * | 2021-06-04 | 2023-12-15 | 南京大学 | 一种基因组件、含有此基因组件的递送系统及其应用 |
WO2024089663A1 (en) | 2022-10-27 | 2024-05-02 | Universidade De Coimbra | Modified cellular by-product, methods and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
EP1735443A2 (en) | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP4463608B2 (ja) * | 2004-04-19 | 2010-05-19 | 独立行政法人科学技術振興機構 | 変異MJD遺伝子の発現を特異的に抑制するsiRNA |
US20150315595A1 (en) * | 2012-03-12 | 2015-11-05 | Santaris Pharma A/S | Compositions and Methods for Modulation of ATXN3 Expression |
LT3237618T (lt) * | 2014-12-24 | 2019-07-10 | Uniqure Ip B.V. | Rnri sukeltas hantingtino geno slopinimas |
JP2018506304A (ja) * | 2015-02-10 | 2018-03-08 | ジェンザイム・コーポレーション | バリアントRNAi |
WO2018002886A1 (en) * | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia 3 (sca3) and other related disorders |
US10457940B2 (en) * | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
-
2020
- 2020-01-09 BR BR112021013109-4A patent/BR112021013109A2/pt unknown
- 2020-01-09 PE PE2021001105A patent/PE20211890A1/es unknown
- 2020-01-09 AU AU2020206617A patent/AU2020206617A1/en active Pending
- 2020-01-09 CA CA3125310A patent/CA3125310A1/en active Pending
- 2020-01-09 US US17/422,083 patent/US20220098592A1/en active Pending
- 2020-01-09 WO PCT/IB2020/050141 patent/WO2020144611A1/en unknown
- 2020-01-09 JP JP2021540046A patent/JP2022516779A/ja active Pending
- 2020-01-09 EP EP20706805.7A patent/EP3908658A1/en active Pending
- 2020-01-09 CN CN202080008549.9A patent/CN113302302A/zh active Pending
- 2020-01-09 MX MX2021008331A patent/MX2021008331A/es unknown
-
2021
- 2021-06-16 CO CONC2021/0007901A patent/CO2021007901A2/es unknown
- 2021-06-22 CL CL2021001680A patent/CL2021001680A1/es unknown
- 2021-07-08 IL IL284717A patent/IL284717A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020206617A1 (en) | 2021-08-26 |
CL2021001680A1 (es) | 2022-02-04 |
CA3125310A1 (en) | 2020-07-16 |
MX2021008331A (es) | 2021-08-05 |
EP3908658A1 (en) | 2021-11-17 |
CN113302302A (zh) | 2021-08-24 |
IL284717A (en) | 2021-08-31 |
US20220098592A1 (en) | 2022-03-31 |
JP2022516779A (ja) | 2022-03-02 |
CO2021007901A2 (es) | 2021-07-19 |
BR112021013109A2 (pt) | 2021-10-13 |
WO2020144611A1 (en) | 2020-07-16 |
WO2020144611A4 (en) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
US11384355B2 (en) | Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin | |
HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
ES2959815T3 (es) | Edición génica selectiva de alelo y usos de la misma | |
ES2732023T3 (es) | Supresión del gen de la huntingtina inducida por ARNi | |
ES2730393T3 (es) | Tratamiento contra el VHB | |
JP2014527401A5 (es) | ||
PE20211890A1 (es) | Arn bicatenario y usos del mismo | |
JP2018516091A5 (es) | ||
HRP20160261T1 (hr) | Komplementarni antagonisti i njihova uporaba | |
CA2968336A1 (en) | Construct for site directed editing of an adenosine nucleotide in target rna | |
ES2873893T3 (es) | Métodos y composiciones para la inhibición específica de beta-catenina por RNA bicatenario | |
PT1550719E (pt) | Arn de cadeia dupla (arncd), para a inibição da expressão de um gene previamente definido | |
JP2011505833A5 (es) | ||
NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
JP2012503493A5 (es) | ||
EP2023937A4 (en) | RNAI MODULATION OF AHA AND ITS THERAPEUTIC USE | |
PE20230179A1 (es) | Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt) | |
CN116157520A (zh) | 用于基因组编辑的组合物和方法 | |
JP6137484B2 (ja) | 遺伝子発現抑制用二本鎖核酸分子 | |
JP2020503014A5 (es) | ||
US10519447B2 (en) | Therapeutic UNA oligomers and uses thereof | |
WO2016188729A1 (en) | Methods for the therapy of protein-misfolding-diseases | |
RU2021123042A (ru) | Двухнитевая рнк и варианты ее применения | |
WO2008138066A1 (en) | Suppression of viruses involved in respiratory infection or disease |